Indaptus shares surge 11.95% after hours as Maxim Group analyst maintains Buy rating, citing moderate buy consensus.

Indaptus Therapeutics surged 11.95% in after-hours trading following Maxim Group analyst Jason McCarthy's maintenance of a Buy rating on the stock. The analyst's action, despite a mixed track record (0 stars, 33.2% success rate), signaled continued institutional support for the company, which closed near its 52-week high of $3.10. The broader healthcare sector's focus on Indaptus, paired with McCarthy's emphasis on its pipeline advancements like the DECOY20 clinical study, likely fueled the after-hours momentum. Other news, including Fate Therapeutics' Hold rating, did not impact Indaptus's performance.